In a phase 3 trial spanning three years, weekly injections of tirzepatide reduced the risk of Type 2 diabetes by 94%, Eli Lilly said Aug. 20.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
4 updates on Mounjaro, Ozempic
In a phase 3 trial spanning three years, weekly injections of tirzepatide reduced the risk of Type 2 diabetes by 94%, Eli Lilly said Aug. 20.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis